Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bernard J. Escudier, Brian I. Rini, Jean-Francois Martini, Wayne Yen-Hwa Chang, Jan Breza, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D. Goddard, Patricia A English, Rachel Li, Xun Lin, Olga Valota, Giacomo Cartenì, Michael D. Staehler, Robert J. Motzer, Alain Ravaud
Institutions: Institut Gustave Roussy, Cleveland Clinic, Pfizer (United States), Taipei Veterans General Hospital, Slovak Medical University, Charité - Universitätsmedizin Berlin, Genomic Health (United States), Ospedale Antonio Cardarelli, Ludwig-Maximilians-Universität München, Memorial Sloan Kettering Cancer Center, Hôpital Saint-André
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2734476107